Sex‐ and Age‐Dependent Outcomes of Cryoablation in Atrial Fibrillation: A 3‐ and 6‐Month Post‐Procedural QoL Analysis Authors: Fotini Mitropoulou, Dimitris Tsiachris, Ioannis Doundoulakis, Stergios Soulaidopoulos, Dimitrios Delialis, Konstantinos Tsioufis, Antonis S Manolis Published: 2026 ABSTRACT ABSTRACTBackgroundCryoablation is an established treatment for atrial fibrillation (AF), offering effective rhythm control and symptomatic improvement. However, short‐term trajectories of quality‐of‐life (QoL) recovery—particularly regarding age‐ and sex‐related differences—remain insufficiently characterized. This study evaluated patterns of functional and emotional improvement within 3 and 6 months after cryoablation.MethodsA prospective observational cohort of 150 patients undergoing cryoablation for AF was analyzed. QoL was assessed using the 36‐item short form (SF) (Physical and Mental Component Scores PCS and MCS) survey at baseline, 3 months, and 6 months.ResultsSignificant improvements were observed across all SF‐36 (57.5 at baseline to 77.1 at 3‐months and 80.1 at 6‐months, p < 0.001), PCS and MCS between baseline and follow‐up (main effect of time p < 0.001). An age × time interaction showed that younger patients (≤ 65 years) demonstrated greater functional gains both in 3 and 6 months compared to older adults (p < 0.001 for all). A sex × time interaction was also noted for SF‐36 (p = 0.046) and PCS (p = 0.038), reflecting a trend for a more rapid improvement in men versus women. These sex differences were non‐significant after Bonferroni adjustment. Multivariable regression confirmed younger age as the strongest independent predictor of improvement (β = 18.2, p < 0.001), followed by paroxysmal AF type and baseline ejection fraction.ConclusionsCryoablation leads to substantial QoL improvements. While age is a robust independent predictor of recovery, sex‐specific differences in physical and emotional trajectories appear as notable trends requiring further investigation. These findings emphasize the need for individualized post‐procedural counseling and follow‐up tailored to demographic recovery profiles.Keywords: atrial fibrillation (AF), cryoablation, minimally invasive therapy, patient outcomes, quality of life (QoL) Introduction Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting more than 33 million individuals globally and contributing substantially to cardiovascular morbidity, mortality, and healthcare utilization [1]. AF is associated with increased risks of stroke, heart failure, hospitalizations, and impaired functional capacity, while its symptom burden—often including palpitations, dyspnea, fatigue, and exercise intolerance—significantly reduces health‐related quality of life (QoL) [1, 2]. Although pharmacological rhythm and rate control strategies remain first‐line therapies, their effectiveness is limited by modest long‐term efficacy, side effects, and high rates of treatment discontinuation [3, 4]. Catheter ablation, particularly pulmonary vein isolation (PVI), has emerged as a preferred strategy for patients with symptomatic, drug‐refractory AF [2, 3, 4] due to its effectiveness, reproducibility, and favorable safety profile [5, 6] compared to radiofrequency ablation [7, 8]. Multiple randomized trials and registries, including FIRE AND ICE and RECABA, have demonstrated the effectiveness of cryoablation in reducing AF recurrence and improving symptoms [9, 10]. Beyond rhythm outcomes, cryoablation has been shown to provide clinically meaningful improvements in QoL, reflecting reductions in symptom severity, psychological distress, and activity limitations [11, 12]. However, the degree and trajectory of QoL recovery after ablation vary substantially across patient populations. Emerging evidence suggests that demographic factors—including age and sex—may influence AF presentation, symptom perception, procedural outcomes, and QoL improvement after ablation. Women often report a greater symptomatic burden, lower baseline QoL, and delayed referral for ablation, while frequently experiencing higher procedural anxiety and stronger symptom–emotion associations [13, 14]. Similarly, older adults tend to have reduced functional reserve, more comorbidities, and distinct recovery patterns despite achieving comparable rhythm control [15, 16]. Yet, despite these observations, few studies have examined how age‐ and sex‐specific differences influence short‐term QoL improvement following cryoablation using validated instruments such as the SF‐36. Understanding these demographic‐specific recovery trajectories is essential for optimizing patient selection, counseling, and tailoring post‐procedural care strategies that extend beyond rhythm control alone. This study aims to evaluate age‐ and sex‐related differences in QoL outcomes at 3 and 6 months following cryoablation for AF, using standardized SF‐36 domains and clinically relevant thresholds of improvement. Methods Study Population, Data Source and Protocol A prospective observational study was conducted on a cohort of 150 patients who presented at the General Hospital of Athens “Hippokration” for cryoablation treatment of AF. The study population comprised individuals aged 18–75 years diagnosed with either paroxysmal or persistent AF. All patients reported symptoms such as dizziness, palpitations, dyspnea, and easy fatigability. Notably, approximately 9%–11% of the participants were undergoing the cryoablation procedure for the second time. Upon hospital admission, patients provided comprehensive medical histories, which included demographic characteristics, clinical symptoms, comorbidities, current pharmacological treatments, and laboratory findings. Each patient provided written informed consent to participate in the study. Before undergoing the procedure, patients completed a validated health‐related QoL questionnaire, the SF‐36 (36‐Item Short Form Health Survey), to assess their baseline QoL. Follow‐up assessments were conducted with on‐site visits at 3 and 6 months post‐procedure, ensuring continuous monitoring of the patients' clinical status and QoL. Rhythm success was defined as the absence of AF, atrial flutter, or atrial tachycardia lasting ≥ 30 s after a 3‐month blanking period. Rhythm status was evaluated at 3 and 6 months via 12‐lead ECG, supplemented by a 24‐h Holter monitor at the 6‐month visit. All participants provided written consent form prior to study enrollment. The study was conducted in accordance with the principles of the Declaration of Helsinki. The study protocol was approved by the Ethics Committee of Hippokrateion General Hospital, Athens, Greece (Approval number: 22.06.2021, 9650). SF‐36 Health‐Related QoL Questionnaire Health‐related QoL was assessed using the validated 36‐Item Short Form Health Survey (SF‐36), which evaluates eight domains of physical and mental health: physical functioning, role‐physical, bodily pain, general health, vitality, social functioning, role‐emotional, and mental health. Assessments were conducted at baseline (pre‐procedure), 3 months, and 6 months post‐cryoablation. To ensure data integrity, patients were required to complete at least 80% of the items within each domain for their scores to be considered valid for analysis. Raw scores were transformed to a 0–100 scale for each domain, with higher scores indicating better perceived health status. Physical component summary (PCS) and mental component summary (MCS) scores were computed using established scoring algorithms. Patients were required to complete at least 80% of items in each domain for valid scoring. The Greek‐validated version of the SF‐36 was used, and Greek population normative values were applied for standardized scoring [17]. Statistical Analysis Continuous variables are reported as mean ± standard deviation (SD) or median (interquartile range) according to distribution; categorical variables are reported as counts and percentages. Normality of continuous variables was assessed with the Shapiro–Wilk test. Baseline comparisons between groups (sex, age ≤ 65 vs. > 65) were performed with the independent samples t‐test for normally distributed continuous variables or the Mann–Whitney U test for non‐normal distributions. Categorical variables were compared using Pearson's chi‐square test or Fisher's exact test when expected cell counts were small. To account for the longitudinal nature of the data and the correlation between repeated measurements within the same individuals, a Repeated‐Measures Mixed‐Effects Model was employed. This model evaluated the Main Effect of Time across the three assessment points and formally tested for Group × Time interactions to identify distinct recovery trajectories based on age (≤ 65 vs. > 65 years) and sex (Men vs. Women). Multivariable linear regression analysis was performed to identify independent predictors of the 6‐month absolute change in SF‐36 scores. This model adjusted for baseline differences in clinical and structural parameters, including hypertension, diabetes, AF type (paroxysmal vs. persistent), left atrial diameter, ejection fraction, and baseline QoL scores. To mitigate the risk of Type I error inflation due to multiple outcomes and timepoints, a hierarchical testing approach was adopted. The change in total SF‐36 score at 6 months was defined as the primary outcome, while component summaries (PCS, MCS) and 3‐month intervals were treated as secondary outcomes. To further address potential error inflation from multiple subgroup comparisons (age and sex) across different timepoints, we applied a Bonferroni adjustment for all post hoc and subgroup analyses. Specifically, since we conducted parallel primary comparisons for two main demographic factors (Age and Sex), the adjusted significance threshold was set at a = 0.025. Furthermore, for the longitudinal comparisons across three timepoints (baseline, 3 months, and 6 months), the threshold for specific pairwise comparisons was adjusted accordingly. A p‐value < 0.05 was considered statistically significant. All analyses were performed using IBM SPSS Statistics version 27. Results Baseline Characteristics of the Study The study population consisted of 150 patients (73.2% male), with a mean age of 61.65 ± 9.92 years. Cardiometabolic comorbidities were common, including hypertension in 57.0%, diabetes in 43.0%, and dyslipidemia in 58.4% of patients (Table 1). Paroxysmal AF accounted for 55.0% of cases. Patients older than 65 years exhibited significantly higher rates of hypertension (68.5% vs. 45.2%), diabetes (53.2% vs. 33.5%), and dyslipidemia (64.2% vs. 50.1%), as well as larger left atrial diameter and lower ejection fraction (all p < 0.05) (Table 1). Women had slightly lower baseline SF‐36 scores and a higher prevalence of hypertension and diabetes compared with men, although differences were not statistically significant (Table 1). Rhythm stability at 6 months was achieved in 81.2% of patients, with higher rates in younger individuals (88.1%) and men (84.5%). TABLE 1Population characteristics by age and sex.CharacteristicOverall (N = 150)Male (N = 110)Female (N = 40)< 65 Years (N = 95)> 65 Years (N = 55) p Total patients150110409555—Age years, (SD)61.65 (9.92)62.1 (9.4)59.8 (10.2)49.2 (3.8)69.7 (4.5)< 0.001Hypertension, %, (n)57.0 (85)55.5 (61)61.3 (25)45.2 (43)68.5 (38)0.048Diabetes, %, (n)43.0 (65)40.9 (45)48.2 (19)33.5 (34)53.2 (29)0.032Dyslipidemia, %, (n)58.4 (87)59.1 (65)56.3 (22)50.1 (48)64.2 (35)0.061Smoking, %, (n)71.8 (107)72.7 (80)69.5 (28)67.2 (63)76.5 (42)0.075Paroxysmal AF, %, (n)55.0 (83)56.4 (62)51.2 (21)60.3 (57)48.2 (26)0.029Left atrial diameter mm, (SD)29.7 (2.27)30.1 (2.5)29.2 (12)28.5 (1.9)31.1 (2.7)0.044Ejection fraction, % (SD)52.58 (5.93)53.2 (5.8)51.4 (5.5)55.1 (6.1)50.3 (5.2)0.025Creatinine mg/dL, (SD)0.82 (0.34)0.81 (0.32)0.84 (0.37)0.76 (0.28)0.89 (0.41)0.072Rhythm stability at 6 months81.2 (121)84.5 (92)74.6 (29)88.1 (84)75.4 (41)0.07 Population characteristics by age and sex. Overall Population Outcomes Significant improvements were observed across all SF‐36 domains, PCS, and MCS between baseline and the 6‐month follow‐up for the whole population (Main Effect of Time: p < 0.001). Overall SF‐36 scores increased from 57.5 at baseline to 77.1 at 3 months and 80.1 at 6 months (p < 0.001) (Table 2, Figure 1A). While the entire cohort benefited, the repeated‐measures mixed‐effects model identified a significant age × time interaction (p < 0.001) (Table 2), confirming that younger patients achieved faster and more substantial gains compared to older adults. Specifically, younger patients (≤ 65 years) demonstrated the most substantial functional gains at both 3 and 6 months compared to older participants (p < 0.001 for all) (Table 2, Figure 1B). These results did not alter after a Bonferroni‐adjusted significance threshold of p < 0.025 for subgroup interactions (Table 2). Older patients (> 65 years) exhibited a non‐significant trend for improvement; their recovery was attenuated, and they were significantly less likely to achieve a ≥ QoL improvement (OR 0.52, p = 0.003). TABLE 2Changes in SF‐36 and primary components values across study's timepoints.GroupBaseline3 months6 months p (0–3 months) p (0–6 months)Repeated measures p Overall57.5 (11.5)77.1 (15.4)80.1 (16.) < 0.001 < 0.001 < 0.001 a Men58.2 (11.6)82.9 (16.6)83.5 (16.7) < 0.001 < 0.001 0.046 b , ns Women55.1 (11.0)70.4 (14.1)78.3 (15.7)0.03ns 0.01 ≤ 65 years58.0 (11.6)85.4 (17.2)88.4 (17.7) < 0.001 < 0.001 < 0.001 b > 65 years55.0 (11.3)63.3 (12.7)67.2 (13.4)0.042ns 0.02ns Overall PCS44.0 (8.8)57.4 (11.5)60.2 (12.0) < 0.001 < 0.001 < 0.001 a Men PCS44.5 (8.9)59.8 (12.0)61.2 (12.2) < 0.01 < 0.01 0.038 b , ns Women PCS43.0 (8.6)53.7 (10.7)58.9 (11.8)0.03ns 0.01 Age ≤ 65 PCS44.0 (8.8)60.1 (12.0)62.9 (12.6) < 0.001 < 0.001 < 0.001 b Age > 65 PCS43.0 (8.6)49.5 (9.9)52.4 (10.5)0.06ns 0.02 Overall MCS47.0 (9.4)59.5 (11.9)61.9 (12.4) < 0.001 < 0.001 < 0.001 a Men MCS47.5 (9.5)59.1 (11.8)60.9 (12.2) 0.04 0.03 Women MCS46.0 (9.2)57.8 (11.6)63.7 (12.7)0.03ns 0.01 0.052 b , ns Age ≤ 65 MCS47.2 (9.4)61.9 (12.4)64.3 (12.9) < 0.001 < 0.001 < 0.001 b Age > 65 MCS46.5 (9.3)53.2 (10.6)56.1 (11.2)0.044ns 0.02ns Note: p‐values are derived from paired t‐test.Abbreviations: MCS, mental component score; PCS, physical component score; SF‐36, short‐form 36. a Repeated measures p‐value for whole population × time is derived from repeated measures mixed‐effects model for SF‐36, PCS and MCS across baseline, 3 months, and 6 months follow‐up across whole population. b Repeated measures p‐value for group × time is derived from repeated measures mixed‐effects model for SF‐36, PCS, and MCS across baseline, 3 months, and 6 months follow‐up by sex and age group.Bold indicates statistical significance after Bonferroni adjustment.ns indicates non‐significant trend after Bonferroni adjustment. Changes in SF‐36 and primary components values across study's timepoints. Note: p‐values are derived from paired t‐test. Abbreviations: MCS, mental component score; PCS, physical component score; SF‐36, short‐form 36. Repeated measures p‐value for whole population × time is derived from repeated measures mixed‐effects model for SF‐36, PCS and MCS across baseline, 3 months, and 6 months follow‐up across whole population. Repeated measures p‐value for group × time is derived from repeated measures mixed‐effects model for SF‐36, PCS, and MCS across baseline, 3 months, and 6 months follow‐up by sex and age group. Bold indicates statistical significance after Bonferroni adjustment. ns indicates non‐significant trend after Bonferroni adjustment. Changes in SF‐36, PCS, and MCS in overall population (A), men versus women (B), and > 65 vs. ≤ 65 years. Bars represent mean of each variable and error bars SD. p‐values are derived from repeated measures mixed‐effects model for whole population × time (A), sex × time (B) and for age × time (C). ** Denotes statistical significance after Bonferroni adjustment. #Denotes non‐significant after Bonferroni adjustment. Sex‐Specific Outcomes Regarding sex‐specific trajectories, a significant sex × time interaction was noted for SF‐36 (p = 0.046) and PCS (p = 0.038), reflecting a front‐loaded physical recovery in men compared to a more gradual trajectory in women (Table 2). Men showed a more pronounced change in SF‐36 from baseline to 3 months compared to women (delta 24.7 vs. 15.3, p = 0.04), though this difference was not sustained at 6 months (p = 0.61). Similarly, men experienced a greater change in PCS at 3 months (delta 15.3 vs. 10.7, p = 0.041), which did not differ at 6 months (p = 0.074). Conversely, women tended to recover faster regarding MCS (p = 0.052), presenting with a marginally higher improvement in emotional well‐being at 6 months compared to men (delta 17.7 vs. 13.4, p = 0.07, Figure 1C). Under a strict Bonferroni‐adjusted significance threshold, these sex‐based differences are interpreted as non‐significant trends (Table 2). Predictors of 6‐Month QoL Improvement Multivariable linear regression identified independent predictors of the 6‐month SF‐36 score change while adjusting for baseline imbalances in comorbidities and cardiac structure. Younger age (≤ 65 years) remained the strongest independent predictor of QoL gains (adjusted β = 18.2; 95% CI: 14.5–21.9; p < 0.001) (Table 3). Sex was not a statistically significant independent predictor of total 6‐month change (β = −2.1; 95% CI: −5.4, –1.2, p = 0.211). Clinical factors also influenced outcomes: patients with paroxysmal AF experienced greater gains than those with persistent AF (β = 4.5, p = 0.012), and a higher baseline ejection fraction was associated with better recovery (β = 0.4 per 1% increase, p = 0.038) (Table 3). Finally, an inverse relationship existed between baseline SF‐36 scores and total improvement (β = −0.6, p < 0.001). Rhythm stability at 6 months was achieved in 81.2% of patients. TABLE 3Adjusted predictors of 6‐month QoL improvement.VariableAdjusted β (coefficient)95% confidence interval p Age (≤ 65 vs. > 65)18.2(14.5, 21.9)< 0.001Sex (female vs. male)−2.1(−5.4, 1.2)0.211AF type (paroxysmal)4.5(1.1, 7.9)0.012Hypertension−3.4(−6.8, −0.1)0.057Ejection fraction (per %)0.4(0.1, 0.7)0.038LA diameter−0.3(−0.9, 0.3)0.412Baseline SF‐36 score−0.6(−0.8, −0.4)< 0.001 Adjusted predictors of 6‐month QoL improvement. Sub‐Analysis A sub‐analysis of patients undergoing repeat cryoablation (n = 15; 10%) revealed that this group had slightly lower baseline MCS (44.2 ± 8.8) and PCS (41.5 ± 8.3) scores compared to the index procedure group, though these differences were not statistically significant (p = 0.18 and p = 0.22, respectively). Both groups achieved significant QoL improvements by 6 months; the redo group showed a mean PCS increase of 14.2 points and an MCS increase of 10.1 points, compared to 16.5 points in PCS (p = 0.29) and 12.8 points in MCS (p = 0.31) in first‐time patients. While the most robust improvements were observed in the 121 patients (81.2%) who maintained rhythm stability, those with documented recurrences still demonstrated a modest QoL benefit. In the recurrence group, PCS improved by 7.8 points and MCS by 6.2 points, which were significantly lower than the 16.8‐point PCS (p < 0.001) and 13.5‐point MCS (p < 0.001) gains observed in those with rhythm stability. Discussion In this prospective cohort of 150 patients undergoing cryoablation for AF, we observed significant improvements in QoL across all major SF‐36 domains at 3 and 6 months. By repeated‐measures mixed‐effects model, we confirmed that while the entire cohort experienced significant gains, these trajectories are heavily influenced by baseline demographic and clinical factors. These findings reinforce the clinical value of cryoablation not only for rhythm control but also for meaningful symptomatic and functional recovery. Our study confirms that cryoablation improves QoL across age groups but demonstrates clear age‐dependent differences in the trajectory and magnitude of recovery. Younger patients (≤ 65 years) demonstrated the most rapid and pronounced improvements, particularly in physical functioning. Younger patients recovered more rapidly and achieved larger functional gains within the first 3 months, whereas older patients showed delayed and attenuated improvements. Older participants also exhibited improvements in physical and emotional function components, albeit these improvements were less pronounced than in younger participants. This discrepancy suggests that factors related to aging, such as reduced functional reserve, greater frailty, and higher burden of comorbidities, may limit the extent of functional recovery even when sinus rhythm is maintained. Specifically, patients over 65 years exhibited significantly higher rates of hypertension and diabetes, which are likely to reduce functional reserve and attenuate the symptomatic benefit of rhythm restoration compared to younger individuals. These findings are consistent with previous AF ablation studies showing attenuated functional improvement in older populations despite comparable procedural success [15, 16, 18, 19, 20]. Regarding sex‐specific trajectories, men presented a trend for more evident benefit in SF‐36 and PCS. In previous AF ablation cohorts, women presented later, with more severe symptoms, and reported more intense AF‐related discomfort than men [21, 22]. Moreover, despite comparable rhythm outcomes between sexes after catheter ablation, women typically report lower baseline QoL and persistently higher symptom perception even when sinus rhythm is maintained [13, 23]. While rhythm stability was comparable between groups, women continued to report higher symptom perception at follow‐up, highlighting the complex interplay between gender and AF‐related discomfort. Notably, our analysis adds to existing findings by showing that emotional well‐being (MCS) improved more substantially in women than in men, suggesting that the psychological and QoL benefits of cryoablation may be particularly pronounced in female patients. Our sub‐analysis of the “redo” population (10% of the cohort) provides additional depth to our findings. Although these patients began with numerically lower baseline MCS and PCS scores, likely reflecting a higher cumulative burden from recurrent AF, their 6‐month recovery magnitude was comparable to those undergoing an index procedure. Furthermore, patients with documented recurrences still demonstrated a modest QoL benefit compared to baseline, potentially due to a reduction in total arrhythmia burden. These preliminary results indicate that cryoablation could provide improvements in QoL even in a redo framework and in AF recurrences. This study has several limitations. First, it was conducted at a single center with a moderate sample size, which may limit the generalizability of the findings. Furthermore, our 81.2% rhythm stability rate reflects ‘real‐world’ clinical follow‐up using intermittent 12‐lead ECGs and 24‐h Holter monitoring rather than continuous trial monitoring (e.g., implantable loop recorders). This approach inherently risks under‐detecting asymptomatic recurrences, which may subtly influence QoL interpretations; specifically, if undetected subclinical AF was present in the ‘stable’ group, the observed QoL benefits might be underestimated. Nevertheless, the significant gains observed reinforce that cryoablation provides meaningful value by reducing the overall arrhythmia burden. Finally, the observational design limits causal interpretation, and unmeasured factors such as physical activity, psychological stress, or medication adherence may have influenced QoL outcomes. These findings highlight distinct age‐ and sex‐related recovery patterns following cryoablation. By utilizing a more rigorous statistical framework, we have demonstrated that while age is a robust independent predictor of recovery, the nuances of sex‐specific trajectories require cautious interpretation. Our results underscore the importance of individualized counseling and follow‐up strategies to optimize patient‐centered outcomes. Author Contributions Study concept and design: F. Mitropoulou and A. S. Manolis. Acquisition of data: F. Mitropoulou, Dimitris Tsiachris, and I. Doundoulakis. Analysis and interpretation of data: F. Mitropoulou, S. Soulaidopoulos and D. Delialis. Drafting of the manuscript: F. Mitropoulou, I. Doundoulakis, and D. Delialis. Critical revision of the manuscript: K. Tsioufis and A. S. Manolis. Ethics Statement The authors have nothing to report. Consent The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments The authors have nothing to report. Data Availability Statement The corresponding author will make data available upon request, excluding confidential information. References Associated Data Data Availability Statement The corresponding author will make data available upon request, excluding confidential information.